For people with the deadly skin cancer melanoma, one dose of the drug Keytruda before surgery might stop the cancer in its tracks, according to a new study published in Nature Medicine.
Keytruda (pembrolizumab) is a PD-1 inhibitor, an immunotherapy drug that triggers the body’s immune response to attack cancer cells. According to results of this study, the drug’s effects peak as early as 7 days after treatment.
Moreover, patients who had a year of this immunotherapy treatment after surgery were free of their cancer for more than 2 years, a media release from HealthDay explains.
“Anti-PD-1 works extremely rapidly, achieving immunological responses peaking in most patients within one to three weeks,” says study co-author John Wherry.
About a third of the patients were “essentially cured within three weeks, highlighting the rapidity of immunotherapy for cancer,” adds Wherry, director of the Penn Institute for Immunology at the University of Pennsylvania.
And in those patients whose cancer returned, researchers found revealing patterns in the way cancer adapts to the drug — discoveries that could lead to better ways to treat such patients.
Keytruda is the drug responsible for the remission of former President Jimmy Carter’s cancer in 2015. Carter, then 90, had melanoma that spread to his brain and liver. Treatment with Keytruda appears to have cured him, the release continues.
For the study, researchers gave 27 patients with advanced melanoma a single dose of Keytruda 3 weeks before surgery.
Eight patients had what researchers described as a complete response, meaning less than 10% of the cancer cells remained at the time of surgery. All eight remained cancer-free for up to 25 months of follow-up.
Researchers also investigated how tumor cells in patients whose cancer returned were able to develop a resistance to Keytruda. The investigators found two causes — tumor mutations and increased activity of cells that naturally suppress the immune system.
Knowing the factors that cause a lack of response to the drug may help to identify patients who might benefit from other therapies in combination with PD-1, Wherry states.